16:44 , May 24, 2018 |  BC Innovations  |  Translation in Brief

Channel for T cell invasion

University of Cincinnati researchers have found that increasing potassium flux through the KCa3.1 channel could boost CD8 + T cell migration into the tumor microenvironment, raising the prospect that this could present a new mechanism...
21:32 , Sep 29, 2017 |  BC Week In Review  |  Financial News

SpringWorks launches with $103M series A

On Sept. 25, SpringWorks Therapeutics LLC (New York, N.Y.) spun out of Pfizer Inc. (NYSE:PFE) with a tranched $103 million series A round led by Bain Capital Life Sciences, Bain Capital Double Impact and OrbiMed....
21:00 , Sep 29, 2017 |  BioCentury  |  Finance

Spring cleaning

SpringWorks Therapeutics LLC aims to partner with pharmas and big biotechs seeking a development path for clinical stage assets outside of their core therapeutic areas. With its tranched $103 million series A round, the newco...
11:02 , Sep 25, 2017 |  BC Extra  |  Financial News

SpringWorks launches with $103M series A

SpringWorks Therapeutics LLC (New York, N.Y.) spun out of Pfizer Inc. (NYSE:PFE) with a tranched $103 million series A round led by Bain Capital Life Sciences, Bain Capital Double Impact and OrbiMed. Pfizer and LifeArc...
19:07 , May 2, 2017 |  BC Extra  |  Financial News

Tetragenetics gets JDRF investment

JDRF T1D Fund invested an undisclosed amount in Tetragenetics Inc. (Cambridge, Mass.), the company said. Tetragenetics is developing mAbs targeting potassium channel Kv1.3 (KCNA3) to treat Type I diabetes. Tetragenetics said that by targeting ion...
07:00 , Jun 28, 2012 |  BC Innovations  |  Strategy

Pharma compounds at the crossroads

The National Center for Advancing Translational Sciences (NCATS) has disclosed details about the first library of therapeutics in its Discovering New Therapeutic Uses for Existing Molecules program ( see "Repurposing pharma compounds"). The compounds provided...
08:00 , Jan 21, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Inflammatory bowel disease (IBD); Crohn's disease Potassium channel KCa3.1 (KCNN4) Studies in murine cells and in mice suggest that inhibiting KCNN4 could help treat...
07:00 , Sep 7, 2009 |  BC Week In Review  |  Clinical News

Senicapoc: Preliminary Phase IIa data

Top-line data from 31 evaluable patients in a double-blind, U.K. Phase IIa trial showed that senicapoc missed the primary endpoint of reducing late asthmatic response ( LAR ) to an inhaled allergen challenge vs. placebo....
07:00 , Aug 20, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Renal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Renal disease Renal damage Potassium channel KCa3.1 (KCNN4) Studies in rodents suggest that inhibiting KCNN4 could help treat renal fibrosis. In a mouse model of renal...
07:00 , Jun 22, 2009 |  BC Week In Review  |  Clinical News

Senicapoc: Completed Phase II enrollment

Icagen completed enrollment of about 70 patients in a double-blind, placebo-controlled, U.S. Phase II trial evaluating 40 mg of oral senicapoc given once daily for 4 weeks. Icagen Inc. (NASDAQ:ICGN), Research Triangle Park, N.C.  ...